ReviewBioMed research international2013
Patent ductus arteriosus in preterm infants: do we have the right answers?
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Related Factors of Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-Analysis.Frontiers in pediatrics · 2020Pooled it
- Article
- A comparison of different dosing regimen of intravenous paracetamol for hemodynamically significant patent ductus arteriosus closure in premature neonates <32 weeks: a prospective observational study.Journal of perinatology : official journal of the California Perinatal Association · 2024Observational
- Factors Predicting Spontaneous Closure of Patent Ductus Arteriosus in Very Low Birth Weight Neonates.Cureus · 2024Article
- Impact of Early Surfactant Administration on Ductus Arteriosus Assessed at 24 h in Preterm Neonates Less than 32 Weeks of Gestational Age.Biomedicines · 2024Article
- Risk stratification of hemodynamically significant patent ductus arteriosus by clinical and genetic factors.World journal of pediatrics : WJP · 2023Article
- Predictive Tool for Closure of Ductus Arteriosus with Pharmacologic or Surgical Treatment in Preterm Infants.Pediatric cardiology · 2022Observational
- Management of Patent Ductus Arteriosus in Premature Infants in 2020.Frontiers in pediatrics · 2020Review
- Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol.Frontiers in pediatrics · 2020Article
- Echocardiographic Diagnosis and Hemodynamic Evaluation of Patent Ductus Arteriosus in Extremely Low Gestational Age Newborn (ELGAN) Infants.Frontiers in pediatrics · 2020Article
- Early Urinary Metabolomics in Patent Ductus Arteriosus Anticipates the Fate: Preliminary Data.Frontiers in pediatrics · 2020Article
- Duration of significant patent ductus arteriosus and bronchopulmonary dysplasia in extremely preterm infants.Journal of perinatology : official journal of the California Perinatal Association · 2019Article
- Base excess and hematocrit predict response to indomethacin in very low birth weight infants with patent ductus arteriosus.Italian journal of pediatrics · 2019Observational
- Paracetamol in Patent Ductus Arteriosus Treatment: Efficacious and Safe?BioMed research international · 2017Review
- Persistent Ductus Arteriosus in Critically Ill Preterm Infants.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2016Article
- [Factors influencing the prognosis of patent ductus arteriosus in very low birth weight infants].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2016Article
- Clinical pharmacology of paracetamol in neonates: a review.Current therapeutic research, clinical and experimental · 2015Review
- Evaluation of Left to Right Shunts by the Pediatrician: How to Follow, When to Refer for Intervention?Indian journal of pediatrics · 2015Review
- Article
- Thromboxane A(2) receptor stimulation promotes closure of the rat ductus arteriosus through enhancing neointima formation.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patent ductus arteriosus (PDA) is a common clinical condition in preterm infants. Preterm newborns with PDA are at greater risk for several morbidities, including higher rates of bronchopulmonary dysplasia (BPD), decreased perfusion of vital organs, and mortality. Therefore, cyclooxygenase (COX) inhibitors and surgical interventions for ligation of PDA are widely used. However, these interventions were reported to be associated with side effects. In the absence of clear restricted rules for application of these interventions, different strategies are adopted by neonatologists. Three different approaches have been investigated including prophylactic treatment shortly after birth irrespective of the state of PDA, presymptomatic treatment using echocardiography at variable postnatal ages to select infants for treatment prior to the duct becoming clinically significant, and symptomatic treatment once PDA becomes clinically apparent or hemodynamically significant. Future appropriately designed randomized controlled trials (RCTs) to refine selection of patients for medical and surgical treatments should be conducted. Waiting for new evidence, it seems wise to employ available clinical and echocardiographic parameters of a hemodynamically significant (HS) PDA to select patients who are candidates for medical treatment. Surgical ligation of PDA could be used as a back-up tool for those patients who failed medical treatment and continued to have hemodynamic compromise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.